This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 **(Currently Amended)** A compound of formula I



I

in which

R^1 is H, OH, CN, Hal, CONHR, OB, CO_2B, CF_3, NR_2, NRCOR, NRCOOR or $NRCONR_2$,

R^2 is NR_2, NRCOR, NRCOOR, $NRCONR_2$, NO_2, $NRSO_2R_2$, NRCSR or $NRCSNR_2$,

R^3 is H, OH, CN, Hal, CONHR, OB, CO_2B, CF_3, NO_2, NR_2, NRCOR, NRCOOR or $NRCONR_2$,

R, independently of one another, are H, B, Het or Ar,

A is a straight-chain or branched, mono- or polyunsaturated carbon chain having 2, 3, 4, 5, or 6 carbon atoms,

B is a straight-chain or branched alkyl radical having 1, 2, 3, 4, 5 or 6 carbon atoms,

a pharmaceutically usable prodrug, ~~derivative,~~ salt thereof, or a mixture thereof in all ratios.

Claim 2 **(Previously Presented)** A compound of formula I according to Claim 1, wherein R^1 is CN or Hal.

Claim 3 **(Previously Presented)** A compound of formula I according to Claim 1, wherein R^3 is H.

Claim 4 **(Previously Presented)** A compound of formula I according to Claim 1 wherein R^2 is NRCOR or NRCOOR.

Claim 5 **(Previously Presented)** A compound of formula I according to Claim 1, wherein A is $(CH_2)_m$, where m = 2, 3, 4, 5 or 6.

Claim 6 **(Previously Presented)** A compound of formula I according to Claim 1, wherein R^1 is CN or Hal, and R^3 is H.

Claim 7 **(Previously Presented)** A compound of ~~the~~ formula I according to Claim 1, wherein R^1 is CN, R^3 is H, and A is $(CH_2)_m$, where m = 4.

Claim 8 **(Previously Presented)** A compound of formula I according to Claim 1, wherein R^1 is in position 5 of the indole radical.

Claim 9 **(Currently Amended)** A compound of formula I which is

N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)methylamide,

ethyl (6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate,

methyl N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate,

N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)-2,2-dimethylpropionamide,

3-{4-[4-(3-amino-2-oxo-2H-chromen-6-yl)piperazin-1-yl]butyl}-1H-indole-5-carbonitrile,

or a pharmaceutically usable prodrug, ~~derivative, solvate, stereoisomer~~ or salt thereof.

Claim 10 (Previously Presented) A process for the preparation of compounds of the formula I according to Claim 1, comprising reacting a compound of formula II



II

in which R^2 and R^3 are as defined in Claim 1, with a compound of formula III



III

in which R^1 and A are as defined in Claim 1, and L is Cl, Br, I, OH or a reactively esterified OH group or another readily nucleophilically substitutable leaving group.

Claim 11 (Previously Presented) A process for the preparation of compounds of the formula I according to Claim 1, comprising reacting a compound of formula IV



IV

in which R^3 is as defined in Claim 1, and R^4 is an amino-protecting group or H, in a Michael-analogous reaction, with ethyl nitroacetate and diethylammonium chloride, and subsequently reducing the nitro group to give a compound of formula V



V

and reacting the compound of formula V is reacted with a compound conforming to formula III.

Claim 12 (Canceled)

Claim 13 (Previously Presented) A pharmaceutical composition, comprising an effective amount of a compound of the formula I according to Claim 1, optionally in addition to one or more inert excipients, adjuvants and/or diluents, and a pharmaceutically acceptable carrier.

Claim 14 (Canceled)

Claim 15 **(Currently Amended)** A process for the preparation of a composition according to Claim 13, comprising combining a compound of formula I ~~and, optionally, a further medicament active ingredient is incorporated into~~with one or more inert excipients and/or diluents by non-chemical methods.

Claim 16 **(Canceled)**

Claim 17 **(Previously Presented)** A method for treating depression, strokes, cerebral ischaemia, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, brain or spinal cord trauma, obsessive-compulsive disorder, sleeping disorders, tardive dyskinesia, learning disorders, age-related memory disorders, eating disorders, or sexual dysfunctions, comprising administering to a host in need thereof a compound according to Claim 1.

Claim 18 **(Canceled)**

Claim 19. **(Previously Presented)** A method for treating depression, strokes, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, or Alzheimer's disease, comprising administering to a host in need thereof a compound according to Claim 1.